Related Experiment Video
Updated: May 16, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Huperzine A for mild cognitive impairment.
Jirong Yue1, Bi Rong Dong, Xiufang Lin
1Department of Geriatrics,West ChinaHospital, SichuanUniversity, Chengdu, China.
The Cochrane Database of Systematic Reviews
|December 14, 2012
Summary
Current research on huperzine A for mild cognitive impairment (MCI) is insufficient. More randomized, placebo-controlled trials are needed to determine its efficacy and safety for treating MCI.
Area of Science:
- Neurology
- Pharmacology
Background:
- Mild cognitive impairment (MCI) is a transitional stage between normal aging and dementia.
- Current Alzheimer's treatments targeting acetylcholine are often ineffective and have side effects for MCI.
- Huperzine A shows potential for beneficial effects in MCI management.
Purpose of the Study:
- To evaluate the clinical effectiveness and safety of huperzine A for treating patients with MCI.
Main Methods:
- Comprehensive literature search across multiple databases (ALOIS, MEDLINE, EMBASE, PsycINFO, LILACS, clinicalTrials.gov, ICTRP, CENTRAL, Web of Science) and Chinese databases.
- Included randomized, parallel-group, placebo-controlled trials comparing huperzine A with placebo in MCI patients.
- Independent assessment of study eligibility by two reviewers.
Main Results:
- No eligible randomized placebo-controlled trials were identified.
- A meta-analysis could not be performed due to the lack of suitable studies.
Conclusions:
- Insufficient evidence exists to determine huperzine A's effectiveness for MCI.
- High-quality, randomized, double-blind, placebo-controlled trials are necessary to assess huperzine A's potential in MCI treatment.
Related Concept Videos
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...